Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 (IMPACT-SIRIO 5)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04941105 |
|
Recruitment Status :
Completed
First Posted : June 28, 2021
Last Update Posted : April 21, 2023
|
Sponsor:
Collegium Medicum w Bydgoszczy
Information provided by (Responsible Party):
Jacek Kubica, Collegium Medicum w Bydgoszczy
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | May 17, 2022 |
| Actual Study Completion Date : | May 17, 2022 |